Sarchi Christopher sold $111K of REPL

Sarchi Christopher (Chief Commercial Officer) sold 12,000 shares of Replimune Group, Inc. (REPL) at $9.24 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sarchi Christopher
Published Jun 4, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not introduce new operational/financial information about the company.

02

Market read

Traders may monitor for sentiment drift or additional insider activity, but the 10b5-1 framing limits immediate fundamental read-through.

03

What to watch

The article provides only the sale size/price and 10b5-1 status; it does not indicate whether other insiders sold, whether the plan is part of routine scheduled sales, or any concurrent news.

Relevance 6/10Novelty 3/10Timing: Filed June 3; sale executed June 1 (after-hours disclosure window).

Background

This is an SEC Form 4 insider transaction disclosure (open-market sale) by a named executive of Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

SEC Form 4 shows CCO Sarchi Christopher sold 12,000 shares of Replimune Group at $9.24 on a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; watch for follow-on selling or unusual volume around the filing date.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying company-specific fundamental catalyst; 10b5-1 reduces interpretive weight.

Market effects

Minimal—single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider sales can precede periods of weaker fundamentals; traders may treat it as a caution flag if paired with other negative signals.

Key entities

  • Replimune Group, Inc.

    Subject of the insider transaction disclosure; CCO sold shares under a 10b5-1 plan.

  • Sarchi Christopher

    Chief Commercial Officer who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.